House Bill 75, titled the Pharmaceutical Full Disclosure Act, would require manufacturers of prescription drugs and biological products to include additional information in consumer-facing advertisements shown in North Carolina. Specifically, ads would have to disclose the date the drug or biological product was approved by the FDA for the advertised use, the date it first became available for purchase in the United States, and more detailed clinical-trial information for any side effect that federal law already requires to be listed in the ad.
For each required side effect disclosure, the advertisement would also need to identify the length of the relevant clinical trial, the number of participants, and the frequency of the side effect, either as a count or percentage of participants. The bill defines key terms such as manufacturer, prescription drug, biological product, clinical trial, and regulated advertisement, and it applies to ads published in North Carolina on or after October 1, 2025.
Impact
The bill would add a new section to Chapter 106 of the North Carolina General Statutes and characterize noncompliant pharmaceutical advertising as an unfair or deceptive trade practice. Its practical effect would be to impose new disclosure obligations on drug manufacturers, affiliated entities, and repackagers that market prescription drugs or biological products to North Carolina consumers through television, radio, internet, print, or other media. The act would take effect when it becomes law, but the advertising requirements would apply only to advertisements published on or after October 1, 2025.
Sentiment
There is limited recorded legislative sentiment available because there are no committee transcripts or vote totals in the provided materials. Based on the bill text alone, the measure appears to reflect a consumer-protection approach aimed at increasing transparency about prescription drug advertising and the risks associated with marketed products.
Contention
The main point of contention likely concerns the scope and burden of the new disclosure requirements. Supporters would likely favor greater transparency, while manufacturers and advertisers may object that the bill could make ads more complex, costly, and difficult to present in a consumer-friendly format. Another possible issue is whether North Carolina can or should impose state-level advertising requirements that overlap with federal FDA rules, especially where the bill incorporates federal side-effect disclosure standards but adds additional state-mandated details.